证券记录 · 已归档季度
RPRX
Royalty Pharma plc · Healthcare · Medical - Pharmaceuticals
19被追踪持有人
+1Δ持有人
173.40M持有股份
$6.12B报告持仓市值
+2新建仓位
−2清仓
动量输入（同类管理人）：
持有人广度 +5.6% ·
股份流向 -14.4% ·
净新建仓位 0.0%
· 公式
持有人分散化：持有人数增多，合计持仓比例缩小。
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 302.09K | $16.78M | n/a | n/a |
| Q2 2026 | 146 | 0 | 306.78M | $17.20B | +5 | −4 |
| Q1 2026 | 148 | +6 | 297.67M | $14.26B | +10 | −5 |
| Q4 2025 | 141 | +1 | 305.31M | $11.80B | +2 | n/a |
| Q3 2025 | 19 | +1 | 173.40M | $6.12B | +2 | −2 |
| Q2 2025 | 16 | 0 | 158.26M | $5.71B | n/a | n/a |
| Q1 2025 | 13 | -3 | 61.13M | $1.91B | n/a | −3 |
| Q4 2024 | 16 | +2 | 77.30M | $1.97B | +2 | n/a |
| Q3 2024 | 13 | -1 | 62.78M | $1.78B | +1 | −2 |
| Q2 2024 | 14 | n/a | 58.59M | $1.54B | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Morgan Stanley ✦ | 44.16M | n/a | $1.56B | 0.1% | n/c | 1 | SEC ↗ ×14 |
| 2 | Fidelity (FMR) ✦ | 27.99M | -30.6% | $987.37M | 0.1% | ▼ Trim | 2 | SEC ↗ ×7 |
| 3 | BlackRock ✦ (被动) | 26.20M | +3.0% | $924.35M | 0.0% | ▲ Add | 2 | SEC ↗ ×20 |
| 4 | Baillie Gifford ✦ | 17.37M | -3.6% | $612.90M | 0.5% | ▼ Trim | 6 | SEC ↗ ×4 |
| 5 | Adage Capital Partners ✦ | 11.97M | +99.4% | $422.15M | 0.7% | ▲ Add | 6 | SEC ↗ |
| 6 | The Vanguard Group ✦ (被动) | 10.94M | -69.9% | $385.84M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 7 | State Street Global Advisors ✦ (被动) | 10.27M | +0.8% | $362.42M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Geode Capital Management ✦ (被动) | 7.62M | -6.8% | $268.03M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 9 | JPMorgan Chase ✦ | 3.52M | n/a | $124.16M | 0.0% | n/c | 1 | SEC ↗ ×24 |
| 10 | Arrowstreet Capital ✦ | 3.28M | +10.3% | $115.80M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 11 | Millennium Management ✦ | 2.24M | +379.2% | $78.86M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 1.96M | +12.9% | $69.19M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 13 | Goldman Sachs Group ✦ | 1.65M | n/a | $58.06M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Marshall Wace ✦ | 1.48M | 新增 | $52.34M | 0.1% | New | 1 | SEC ↗ ×2 |
| 15 | Two Sigma Investments ✦ | 1.18M | +2089.0% | $41.78M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 1.03M | +271.9% | $36.37M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 17 | Citadel Advisors ✦ | 394.67K | -25.1% | $13.92M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 140.03K | +314.3% | $4.94M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 19 | Wellington Management ✦ | 6.87K | 新增 | $242,479 | 0.0% | New | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Marshall Wace | $52.34M | 0.1% |
| Wellington Management | $242,479 | 0.0% |
已清仓
| Norges Bank | $181.39M | 曾为 0.0% |
| Viking Global Investors | $93.59M | 曾为 0.3% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 583 持有人, 354.58M 股份, $16.55B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Sep 28
Urist Marshall
Officer · 4.13K 股 · $238,813
Sep 22
Hite Christopher
Officer · 96.07K 股 · $5.62M
Sep 22
Hite Christopher
Officer · 3.93K 股 · $231,403
Aug 18
Hite Christopher
Officer · 100.00K 股 · $6.00M
Aug 13
Coyne Terrance P.
Officer · 9.23K 股 · $540,752
Aug 13
Coyne Terrance P.
Officer · 1.77K 股 · $104,799
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 17
SC 13D/A: Legorreta Pablo G.
18.7% 占股份类别 · 查看 SEC 原始申报文件 ↗
Jun 16
SC 13D/A: Severgnini Achille G.
4.8% 占股份类别 · 查看 SEC 原始申报文件 ↗
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据